A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Chris H. Polman, M.D., Paul W. O'Connor, M.D., Eva Havrdova, M.D., Michael Hutchinson, M.D., Ludwig Kappos, M.D., David H. Miller, M.D., J. Theodore Phillips, M.D., Ph.D., Fred D. Lublin, M.D., Gavin Giovannoni, M.D., Andrzej Wajgt, M.D., Martin Toal, M.B., M.F.P.M., Frances Lynn, M.Sc., Michael A. Panzara, M.D., M.P.H., Alfred W. Sandrock, M.D., Ph.D., for the AFFIRM Investigators
Background Natalizumab is the first 4 integrin antagonist ina new class of selective adhesion-molecule inhibitors. We reportthe results of a two-year phase 3 trial of natalizumab in patientswith relapsing multiple sclerosis.
Methods Of a total of 942 patients, 627 were randomly assignedto receive natalizumab (at a dose of 300 mg) and 315 to receiveplacebo by intravenous infusion every four weeks for more thantwo years. The primary end points were the rate of clinicalrelapse at one year and the rate of sustained progression ofdisability, as measured by the Expanded Disability Status Scale,at two years.
Results Natalizumab reduced the risk of sustained progressionof disability by 42 percent over two years (hazard ratio, 0.58;95 percent confidence interval, 0.43 to 0.77; P<0.001). Thecumulative probability of progression (on the basis of Kaplan–Meieranalysis) was 17 percent in the natalizumab group and 29 percentin the placebo group. Natalizumab reduced the rate of clinicalrelapse at one year by 68 percent (P<0.001) and led to an83 percent reduction in the accumulation of new or enlarginghyperintense lesions, as detected by T2-weighted magnetic resonanceimaging (MRI), over two years (mean numbers of lesions, 1.9with natalizumab and 11.0 with placebo; P<0.001). There were92 percent fewer lesions (as detected by gadolinium-enhancedMRI) in the natalizumab group than in the placebo group at bothone and two years (P<0.001). The adverse events that weresignificantly more frequent in the natalizumab group than inthe placebo group were fatigue (27 percent vs. 21 percent, P=0.048)and allergic reaction (9 percent vs. 4 percent, P=0.012). Hypersensitivityreactions of any kind occurred in 25 patients receiving natalizumab(4 percent), and serious hypersensitivity reactions occurredin 8 patients (1 percent).
Conclusions Natalizumab reduced the risk of the sustained progressionof disability and the rate of clinical relapse in patients withrelapsing multiple sclerosis. Adhesion-molecule inhibitors holdpromise as an effective treatment for relapsing multiple sclerosis.(ClinicalTrials.gov number, NCT00027300
[ClinicalTrials.gov]
.)
Source Information
From the Vrije Universiteit Medical Center, Amsterdam (C.H.P.); St. Michael's Hospital, Toronto (P.W.O.); General Teaching Hospital, Prague, Czech Republic(E.H.); St. Vincent's University Hospital, Dublin, Ireland (M.H.); University Hospital Basel, Basel, Switzerland (L.K.); Institute of Neurology, London (D.H.M., G.G.); Texas Neurology, Dallas (J.T.P.); Mt. Sinai School of Medicine, New York (F.D.L.); Silesian Medical University, Katowice, Poland (A.W.); and Biogen Idec, Cambridge, Mass. (M.T., F.L., M.A.P., A.W.S.).
Address reprint requests to Dr. Polman at the VU Medical Center, P.O. Box 7057, Amsterdam 1007 MB, the Netherlands, or at ch.polman{at}vumc.nl.
Natalizumab for Relapsing Multiple Sclerosis
Tenser R. B., Jeffery D. R., Meyer M. A., Polman C. H., Rudick R. A., Major E. O., Yousry T. A., Clifford D. B., Ropper A. H.
Extract |
Full Text |
PDF
N Engl J Med 2006;
354:2387-2389, Jun 1, 2006.
Correspondence
This article has been cited by other articles:
Cohen, J., Calabresi, P., Chakraborty, S., Edwards, K., Eickenhorst, T., Felton, W. III, Fisher, E., Fox, R., Goodman, A., Hara-Cleaver, C., Hutton, G., Imrey, P., Ivancic, D., Mandell, B., Perryman, J., Scott, T., Skaramagas, T., Zhang, H. for the AC
(2008). Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. Mult Scler
14: 370-382
[Abstract]
Fox, R. J., Kappos, L.
(2008). Is natalizumab overshooting its rebound?. Neurology
70: 1073-1074
[Full Text]
Polman, C. H., Reingold, S. C., Barkhof, F., Calabresi, P. A., Clanet, M., Cohen, J. A., Cutter, G. R., Freedman, M. S., Kappos, L., Lublin, F. D., McFarland, H. F., Metz, L. M., Miller, A. E., Montalban, X., O'Connor, P. W., Panitch, H., Richert, J. R., Petkau, J., Schwid, S. R., Sormani, M. P., Thompson, A. J., Weinshenker, B. G., Wolinsky, J. S.
(2008). Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment. Neurology
70: 1134-1140
[Abstract][Full Text]
Vellinga, M. M., Castelijns, J. A., Barkhof, F., Uitdehaag, B.M.J., Polman, C. H.
(2008). POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS. Neurology
70: 1150-1151
[Full Text]
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., Langer-Gould, A., Smith, C. H., the HERMES Trial Group,
(2008). B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis. NEJM
358: 676-688
[Abstract][Full Text]
Mullen, J. T., Vartanian, T. K., Atkins, M. B.
(2008). Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis. NEJM
358: 647-648
[Full Text]
Kos, D., Kerckhofs, E., Nagels, G., D'hooghe, M.B., Ilsbroukx, S.
(2008). Origin of Fatigue in Multiple Sclerosis: Review of the Literature. Neurorehabil Neural Repair
22: 91-100
[Abstract]
Le Page, E., Leray, E., Taurin, G., Coustans, M., Chaperon, J., Morrissey, S. P, Edan, G.
(2008). Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J. Neurol. Neurosurg. Psychiatry
79: 52-56
[Abstract][Full Text]
Frohman, E. M., Costello, F., Stuve, O., Calabresi, P., Miller, D. H., Hickman, S. J., Sergott, R., Conger, A., Salter, A., Krumwiede, K. H., Frohman, T. C., Balcer, L., Zivadinov, R.
(2008). Modeling Axonal Degeneration Within the Anterior Visual System: Implications for Demonstrating Neuroprotection in Multiple Sclerosis. Arch Neurol
65: 26-35
[Abstract][Full Text]
Cabrelle, A., Dell'Aica, I., Melchiori, L., Carraro, S., Brunetta, E., Niero, R., Scquizzato, E., D'Intino, G., Calza, L., Garbisa, S., Agostini, C.
(2008). Hyperforin down-regulates effector function of activated T lymphocytes and shows efficacy against Th1-triggered CNS inflammatory-demyelinating disease. J. Leukoc. Biol.
83: 212-219
[Abstract][Full Text]
Doring, A., Wild, M., Vestweber, D., Deutsch, U., Engelhardt, B.
(2007). E- and P-Selectin Are Not Required for the Development of Experimental Autoimmune Encephalomyelitis in C57BL/6 and SJL Mice. J. Immunol.
179: 8470-8479
[Abstract][Full Text]
Lee, S.-U., Grigorian, A., Pawling, J., Chen, I-J., Gao, G., Mozaffar, T., McKerlie, C., Demetriou, M.
(2007). N-Glycan Processing Deficiency Promotes Spontaneous Inflammatory Demyelination and Neurodegeneration. J. Biol. Chem.
282: 33725-33734
[Abstract][Full Text]
Foster, C. A., Howard, L. M., Schweitzer, A., Persohn, E., Hiestand, P. C., Balatoni, B., Reuschel, R., Beerli, C., Schwartz, M., Billich, A.
(2007). Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis. J. Pharmacol. Exp. Ther.
323: 469-475
[Abstract][Full Text]
Calabresi, P. A., Giovannoni, G., Confavreux, C., Galetta, S. L., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., O'Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E. -W., Rudick, R. A., Stuart, W. H., Lublin, F. D., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., For the AFFIRM and SENTINEL Investigators,
(2007). The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology
69: 1391-1403
[Abstract][Full Text]
MARECKOVA, H., HAVRDOVA, E., KRASULOVA, E., VANKOVA, Z., KOBEROVA, M., STERZL, I.
(2007). Natalizumab in the Treatment of Patients with Multiple Sclerosis: First Experience. Ann. N. Y. Acad. Sci.
1110: 465-473
[Abstract][Full Text]
Krumbholz, M., Pellkofer, H., Gold, R., Hoffmann, L. A., Hohlfeld, R., Kumpfel, T.
(2007). Delayed Allergic Reaction to Natalizumab Associated With Early Formation of Neutralizing Antibodies. Arch Neurol
64: 1331-1333
[Abstract][Full Text]
Shindler, K. S., Ventura, E., Rex, T. S., Elliott, P., Rostami, A.
(2007). SIRT1 Activation Confers Neuroprotection in Experimental Optic Neuritis. IOVS
48: 3602-3609
[Abstract][Full Text]
Grigorian, A., Lee, S.-U., Tian, W., Chen, I.-J., Gao, G., Mendelsohn, R., Dennis, J. W., Demetriou, M.
(2007). Control of T Cell-mediated Autoimmunity by Metabolite Flux to N-Glycan Biosynthesis. J. Biol. Chem.
282: 20027-20035
[Abstract][Full Text]
Ransohoff, R. M.
(2007). Natalizumab for Multiple Sclerosis. NEJM
356: 2622-2629
[Full Text]
Dhib-Jalbut, S.
(2007). Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology
68: S13-S21
[Abstract][Full Text]
Khan, O.
(2007). Can clinical outcomes be used to detect neuroprotection in multiple sclerosis?. Neurology
68: S64-S71
[Abstract][Full Text]
Arnold, D. L.
(2007). Evidence for neuroprotection and remyelination using imaging techniques. Neurology
68: S83-S90
[Abstract][Full Text]
Dorsey, E. R., Thompson, J. P., Noyes, K., Dick, A. W., Holloway, R. G., Schwid, S. R.
(2007). Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology
68: 1524-1528
[Abstract][Full Text]
Miller, D. H., Soon, D., Fernando, K. T., MacManus, D. G., Barker, G. J., Yousry, T. A., Fisher, E., O'Connor, P. W., Phillips, J. T., Polman, C. H., Kappos, L., Hutchinson, M., Havrdova, E., Lublin, F. D., Giovannoni, G., Wajgt, A., Rudick, R., Lynn, F., Panzara, M. A., Sandrock, A. W., For the AFFIRM Investigators,
(2007). MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology
68: 1390-1401
[Abstract][Full Text]
Balcer, L. J., Galetta, S. L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F. D., Miller, D. H., O'Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E. -W., Rudick, R. A., Stuart, W. H., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., for the AFFIRM and SENTINEL Investigators,
(2007). Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology
68: 1299-1304
[Abstract][Full Text]
Pohl, D., Waubant, E., Banwell, B., Chabas, D., Chitnis, T., Weinstock-Guttman, B., Tenembaum, S., for the International Pediatric MS Study Group,
(2007). Treatment of pediatric multiple sclerosis and variants. Neurology
68: S54-S65
[Abstract][Full Text]
Sweet, B. V.
(2007). Natalizumab update. Am J Health Syst Pharm
64: 705-716
[Abstract][Full Text]
Choudry, B. A., Chan, J. W.
(2007). An Update on Monoclonal Antibody Therapies in Multiple Sclerosis. Journal of Pharmacy Practice
20: 167-180
[Abstract]
Khalili, K., White, M. K., Lublin, F., Ferrante, P., Berger, J. R.
(2007). Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology
68: 985-990
[Abstract][Full Text]
Stuve, O., Marra, C. M., Cravens, P. D., Singh, M. P., Hu, W., Lovett-Racke, A., Monson, N. L., Phillips, J. T., Tervaert, J. W. C., Nash, R. A., Hartung, H.-P., Kieseier, B. C., Racke, M. M., Frohman, E. M., Hemmer, B.
(2007). Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions. Arch Neurol
64: 169-176
[Abstract][Full Text]
Johnston, S. L
(2007). Biologic therapies: what and when?. J. Clin. Pathol.
60: 8-17
[Abstract][Full Text]
Stuve, O., Marra, C. M., Bar-Or, A., Niino, M., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Jerome, K. R., Cook, L., Grand'Maison, F., Hemmer, B., Monson, N. L., Racke, M. K.
(2006). Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.. Arch Neurol
63: 1383-1387
[Abstract][Full Text]
Noseworthy, J. H.
(2006). How much can we learn from long-term extension trials in multiple sclerosis?. Neurology
67: 930-931
[Full Text]
Karni, A., Abraham, M., Monsonego, A., Cai, G., Freeman, G. J., Hafler, D., Khoury, S. J., Weiner, H. L.
(2006). Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response. J. Immunol.
177: 4196-4202
[Abstract][Full Text]
(2006). Other articles noted. Evid. Based Med.
11: 127-128
[Full Text]
Gold, R., Hohlfeld, R.
(2006). Multiple sclerosis therapy: new agents carry new risks. PN
6: 248-251
[Full Text]
Friese, M. A., Montalban, X., Willcox, N., Bell, J. I., Martin, R., Fugger, L.
(2006). The value of animal models for drug development in multiple sclerosis. Brain
129: 1940-1952
[Abstract][Full Text]
Tenser, R. B., Jeffery, D. R., Meyer, M. A., Polman, C. H., Rudick, R. A., Major, E. O., Yousry, T. A., Clifford, D. B., Ropper, A. H.
(2006). Natalizumab for relapsing multiple sclerosis.. NEJM
354: 2387-2389
[Full Text]
(2006). Two-Year Benefit from Natalizumab for MS. JWatch Neurology
2006: 1-1
[Full Text]
(2006). Promise and Peril of Natalizumab for MS. JWatch General
2006: 3-3
[Full Text]
Tonks, A.
(2006). What's new in the other general journals. BMJ
332: 597-598
[Full Text]
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., Sandrock, A. W., the SENTINEL Investigators,
(2006). Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.. NEJM
354: 911-923
[Abstract][Full Text]
Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., Barkhof, F., Radue, E.-W., Jager, H. R., Clifford, D. B.
(2006). Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.. NEJM
354: 924-933
[Abstract][Full Text]
Ropper, A. H.
(2006). Selective treatment of multiple sclerosis.. NEJM
354: 965-967
[Full Text]
4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis. 
Previous
